BioPharma Resources

Drug Trial Radar · NCT07445763

TARSILA Real-World Evidence Study

Real-world Effectiveness of maTernAl RSVpreF vaccInation Against RSV-associated Acute Respiratory ilLness in Infants in BrAzil (TARSILA Study): a Multicentre, Prospective, Test-negative, Case-Control Study

Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

5,000

Planned (sponsor's estimate)

Start

Apr 27, 2026

Primary completion

Sep 30, 2028

Study completion Dec 31, 2028

Sponsor

Lead sponsor
Inova MedicalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Universidade Federal do Paraná
First posted
Mar 3, 2026

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes, up to 360 days
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The overall objective of Tarsila Study is to estimate the real-world vaccine effectiveness of maternal RSVpreF immunization during pregnancy in Brazil against medically attended (inpatient and outpatient) respiratory syncytial virus-associated acute respiratory illness in infants. To achieve this, two multicenter, prospective, test-negative case-control studies will be conducted among infants with ARI: the TARSILA Inpatient Study, evaluating hospitalized infants and the TARSILA Outpatient Study, evaluating infants managed in outpatient settings.

Conditions

  • Respiratory Syncytial Virus (RSV)
  • Maternal Immunization
  • Acute Respiratory Illness (ARI)
  • Lower Respiratory Tract Disease
  • Infant Outcomes

Interventions

  • respiratory syncytial virus bivalent prefusion F vaccineBiological

    For both studies, the primary exposure is maternal receipt of respiratory syncytial virus bivalent prefusion F vaccination during pregnancy in accordance with the Brazilian National Immunization Program recommendation (24⁺⁰/₇ to 36⁺⁶/₇ weeks' gestation) with the receipt of the vaccine 14 days or more before delivery.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Lower respiratory Tract Disease (LRTD) Hospitalization among infants aged up to 180 days (Tarsila Inpatient Study)Time frame: Hospitalization occurring ≤180 days after birth
  2. Acute respiratory illness (ARI) among infants aged up to 180 days (Tarsila Outpatient Study)Time frame: Occurring ≤180 days after birth.

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Unidade de Pronto Atendimento Veneza

    Cascavel, Paraná, Brazil · Recruiting

  • Complexo do Hospital de Clínicas da Universidade Federal do Paraná

    Curitiba, Paraná, Brazil · Recruiting

  • Hospital Infantil Pequeno Príncipe

    Curitiba, Paraná, Brazil · Recruiting

  • Unidade de Pronto Atendimento 24 Horas Dr. Edgar Netzel

    Marechal Cândido Rondon, Paraná, Brazil · Recruiting

  • Unidade de Saúde Central de Palotina

    Palotina, Paraná, Brazil · Recruiting

  • Unidade de Pronto Atendimento II de Toledo

    Toledo, Paraná, Brazil · Recruiting

  • Hospital de Clínicas de Porto Alegre

    Porto Alegre, Rio Grande do Sul, Brazil · Recruiting

  • Hospital Nossa Senhora da Conceição

    Porto Alegre, Rio Grande do Sul, Brazil · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.